CJC-1295
Tetrasubstituted 29-amino-acid peptide with Drug Affinity Complex (DAC)
A long-acting GHRH analogue studied in small 2006 human trials for raising growth hormone and IGF-1.
CJC-1295 is a synthetic analogue of growth hormone-releasing hormone (GHRH) with a Drug Affinity Complex (DAC) attached. The DAC lets it bind to albumin in the blood, which stretched its half-life to about 6-8 days in human studies. In two small 2006 trials in healthy adults, one injection kept growth hormone (GH) and insulin-like growth factor 1 (IGF-1) above baseline for 1-2 weeks. No trial has measured muscle or fat outcomes, and FDA's 2024 review found no human effectiveness data. As of October 2026 it isn't approved as a drug anywhere, and this product is sold for research use only.
Read the research profile for mechanisms, citations, and safety context before comparing vendors. View the CJC-1295 research profile.
Key Benefits
Mechanism of Action
CJC-1295 binds GHRH receptors on the anterior pituitary, prompting it to make and release the body's own growth hormone. Native GHRH is broken down within minutes. The DAC on CJC-1295 binds serum albumin, which protects it from breakdown and keeps it active for days. Vendor copy often describes the result as a steady GH 'bleed', but the one human study that sampled GH every 20 minutes overnight found otherwise. A week after a single injection, natural GH pulses kept their usual frequency and size, while trough GH rose 7.5-fold, mean GH 46% and IGF-1 45% (Ionescu and Frohman, 2006).
Dosing Guidelines
Typical Dose
500-1000 mcg/week
Frequency
1-2x per week
Duration
12-16 weeks
Note: These figures come from vendor and community guidance, not a trial, and we couldn't trace a primary source for the weekly range. Users commonly report subcutaneous injection, often split into two weekly doses near bedtime on an empty stomach; that timing hasn't been tested for CJC-1295. In the 2006 trials, healthy adults got single weight-based doses of 30-250 mcg/kg, or two to three doses given weekly or every other week, and doses of 30-60 mcg/kg were the best tolerated. Most forum users actually describe the no-DAC form (Mod GRF 1-29) at 100-300 mcg with ipamorelin. As of October 2026, WADA prohibits CJC-1295 at all times (S2.2.4).
Research & Studies
How CJC-1295 with DAC raises growth hormone and IGF-1, what the 2006 human studies found, and how users report dosing it.
Read Full ResearchHow a GHRH analogue and a GHRP act on different pituitary receptors, and why users often combine them.
Read Full ResearchWhy users pair a GHRH analogue with a GHRP. No controlled human trial has tested the combination.
Read Full ResearchPotential Side Effects
Reported side effects may include:
- - Injection-site reactions (about 70% after one dose in a 2006 trial; every active-dose participant in a second trial)
- - Flushing, headache, diarrhea and raised heart rate (trials); flushing and head rush are also common in user reports
- - Dizziness, low blood pressure and brief involuntary leg muscle contractions (one 2006 trial)
- - Water retention and tingling or numb hands (user reports)
- - Fatigue or lethargy (user reports)
- - IGF-1 above the normal range at the highest trial dose of 250 mcg/kg (2006 trial)
- - Possible rise in blood glucose (seen with other GH-raising compounds such as MK-677; not studied for CJC-1295)
- - Phase 2 trial stopped after a fatal heart attack the physician blamed on undiagnosed heart disease (unpublished; cited by FDA, 2024)
This information is for research purposes only. Always consult with a healthcare professional.
Popular Stacking Options
CJC-1295 + Ipamorelin
Users commonly pair a GHRH analogue with ipamorelin, a GHRP that acts on a different pituitary receptor, expecting a larger GH release from the two together. No controlled human trial has tested the combination, and most users pair ipamorelin with the no-DAC form (Mod GRF 1-29) rather than CJC-1295 with DAC.
Shop this stackCJC-1295 + Tesamorelin
Some users combine the two, but both are GHRH analogues acting on the same receptor, and no study has tested the pairing. Tesamorelin is an FDA-approved prescription medicine (Egrifta) for excess abdominal fat in HIV-associated lipodystrophy; research-use versions aren't equivalent to it.
Shop this stackCJC-1295 + BPC-157
Users pair them for injury recovery, combining CJC-1295's rise in IGF-1 with BPC-157, whose tissue-repair data come mostly from rodent studies. No study has tested the combination, and as of October 2026 neither is approved as a drug.
Shop this stackFrequently Asked Questions
What's the difference between CJC-1295 with DAC and without DAC (Mod GRF 1-29)?
The main difference is half-life. CJC-1295 with DAC had a half-life of about 6-8 days in 2006 human studies, so trials dosed it weekly or every other week. Mod GRF 1-29 (CJC-1295 without DAC) is short-acting, and users typically report injecting it one or more times a day, usually with ipamorelin. Vendor copy often says the DAC version causes a constant GH 'bleed'. In the one human study that measured overnight GH every 20 minutes, natural pulses kept their timing and size while baseline GH rose. Most forum users describe the no-DAC form.
Will CJC-1295 'shut down' my natural GH production?
We couldn't find a study that measured this directly. CJC-1295 acts through the pituitary's own GH release rather than supplying GH from outside, and in the 2006 trials the rise in IGF-1 after a single dose lasted 9-11 days. Nobody has studied long-term use, and FDA's 2024 review said its long-term safety in humans is unknown, so whether months of dosing change natural GH output is an open question. Talk to a healthcare professional before using any compound that changes hormone levels.
When is the best time to inject CJC-1295?
No trial has tested timing for CJC-1295. Users commonly report injecting before bed, on the idea that it adds to the large natural GH pulse during deep sleep, and on an empty stomach, since food is thought to blunt GH release. With a half-life of about a week, time of day probably matters less for the DAC form; most bedtime advice comes from protocols for short-acting Mod GRF 1-29.
How long does it take to see results from CJC-1295?
There's no tested timeline, because no trial has measured body composition, sleep or recovery with CJC-1295. In the 2006 trials, GH and IGF-1 rose within days of an injection. Vendor and community guides claim better sleep within a couple of weeks and body-composition changes after 4-6 weeks, but these are self-reports, often from people using the no-DAC form with ipamorelin, and we couldn't find a study that measured either.
More from this category
Compare nearby options in the same category before choosing a research product.
GHRP-2
A ghrelin-mimetic secretagogue studied for its strong effect on growth hormone release.
GHRP-6
A ghrelin mimetic studied for growth hormone release, with strong appetite effects reported by users.
Hexarelin
A ghrelin-mimetic GH secretagogue studied for growth hormone release and short-term heart effects.
Ipamorelin
A ghrelin-mimicking peptide studied for growth hormone release, with limited human data
You might also like
These peptides share research keywords or protocol overlap with CJC-1295.
AOD-9604
Growth hormone fragment studied for fat metabolism
IGF-1 LR3
An engineered IGF-1 analogue studied in rat and pig experiments; no human studies have been published.
MK-677
An oral ghrelin mimetic studied in human trials for raising growth hormone and IGF-1.
Ready to Purchase CJC-1295?
Get pharmaceutical-grade CJC-1295 from Simple Peptide with 99%+ purity, third-party lab testing, and same-day dispatch.
Buy CJC-1295 Now